RGDXQ Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 geg. 2023 @ 19:32):

Stats
Šios dienos apimtis	77 000.00
Vidutinė apimtis	0.00
Rinkos kapitalizacija	116.00
EPS	$-0.108 ( 2015-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Tūris Koreliacija

Ilgas: -0.48 (neutral)

Trumpas: 0.00 (neutral)

Signal:(51.968) Neutral

Response Genetics, Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Response Genetics, Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

Response Genetics, Inc Finansinės ataskaitos

Annual	2015
Pajamos:	$18.04M
Bruto pelnas:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2015
Pajamos:	$18.04M
Bruto pelnas:	$3.94M (21.85 %)
EPS:	$-0.521

FY	2014
Pajamos:	$16.72M
Bruto pelnas:	$6.71M (40.12 %)
EPS:	$-0.350

FY	2013
Pajamos:	$19.80M
Bruto pelnas:	$9.35M (47.20 %)
EPS:	$-0.240

Financial Reports:

No articles found.

Response Genetics, Inc

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.